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HaplotypeMultiple sclerosis (MS) is amulti-factorial autoimmune disease of the central nervous system. The exact etiology
ofMS is still unknown. Due to the important roles that cytokines play asmediators in immune and inﬂammatory
responses, we have evaluated the association of IL-1 gene cluster polymorphisms and haplotypes with MS
susceptibility in 306 unrelated MS patients and 312 healthy matched controls. A signiﬁcant association was
found for the IL-1β+3953 T allele [OR = 1.43, 95% CI (1.14–1.79), P value = 0.002, Pc = 0.01] and for IL-1β
+3953 T/T genotype and MS risk [OR = 1.92, 95% CI (1.25–2.96), P value = 0.005, Pc = 0.01]. Interestingly,
the genotypes of the polymorphisms remained signiﬁcant under recessive, co-recessive and dominant models.
However, no signiﬁcant differences were found betweenMS patients and controls in the genotype and allele fre-
quencies of the IL-1β−511,−31 and IL-1Ra polymorphisms. Haplotype analysis for IL-1β−31 and IL-1β−511,
with moderate linkage disequilibrium (LD), using the EM algorithm revealed a signiﬁcant global association of
haplotype differences between the two groups. Lower presence of two haplotypes (H3: C-T andH4: T-C)was ob-
served in the MS patients than healthy controls. However, after applying Bonferroni's correction the differences
were not signiﬁcant. To our knowledge, this is the ﬁrst study reporting the association of the IL-1β+3953 gene
polymorphism and MS susceptibility.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Multiple sclerosis (MS) is a multi-factorial autoimmune disease of
the central nervous system (CNS) in which genetic, environmental
and geographical factors are involved in the etiology of the disease
(Handel et al., 2010, Kallaur et al., 2011). Environmental factors (e.g. vi-
taminD exposure, EBV infection and smoking) interactwith genetic fac-
tors to produce an overall disease risk toMS (Handel et al., 2010, Pravica
et al., 2012). Cytokines are important mediators in immune and inﬂam-
matory responses. Therefore, genes encoding cytokines can be suitable
candidates for investigation into immunoinﬂammatory conditions,
such as multiple sclerosis (Schrijver et al., 2003). Interleukin-1 (IL-1)
is a multifunctional cytokine that is involved in several processes
including immunoregulation, inﬂammation, neurodegeneration and
neuroregeneration (Dinarello, 1996, Dinarello and Wolff, 1993).
Several reports have implicated the role of the IL-1 family in the MS
pathophysiology (Schrijver et al., 2003). On the other hand, the
presence of speciﬁc human gene single nucleotide polymorphisms
(SNPs) in the non-coding regions of genes has been associated withbazi).susceptibility to several diseases (Knight, 2003). The IL-1 gene cluster
is considered logical candidate for the loci determining susceptibility
to the MS disease (Feakes et al., 2000). The IL-1 gene family (IL-1α,
IL-1β and IL-1RA) located in a cluster on the long arm of human
chromosome 2 (2q13–14), have several recognized polymorphisms
(Dinarello, 1996). IL-1α and IL-1β are agonists and IL-1Ra is a speciﬁc
receptor antagonist (Dinarello, 1996). Two biallelic bases-exchange
polymorphism in the IL-1α gene have been described at position
−889 C/T (rs1800587) and+4845 (rs17561), both are C to T single nu-
cleotide polymorphism (SNP) (Erbek et al., 2007,Mcdonald et al., 2001).
The IL-1β gene has three described biallelic polymorphisms at positions
−511 (rs16944),−31 (rs1143627), and +3953 (rs1143634) from the
transcriptional start site, all representing a C to T substitution (El-Omar
et al., 2000, Di Giovine et al., 1992, Pociot et al., 1992). The IL-1Ra gene
(IL-1RN) contains a variable number of tandem repeat (VNTR)
polymorphism of 86 base pairs in intron 2 (Tarlow et al., 1993). The as-
sociation of IL-1 gene polymorphisms with MS susceptibility has been
investigated in several populations (Aggelakis et al., 2010, Borzani
et al., 2010, Crusius et al., 1995, De La Concha et al., 1997, Dominici
et al., 2002, Ferri et al., 2000, Hooper-Van Veen et al., 2003, Huang
et al., 1996, Kantarci et al., 2000, Luomala et al., 2001, Mann et al.,
2002, Mirowska-Guzel et al., 2011, Niino et al., 2001, Sarial et al., 2008,
Table 2
Genotype and allele frequencies of IL-1 gene polymorphisms in MS patients and healthy
controls.
Genotype
and allele
Healthy
controls
(n = 312)
MS patients
(n = 306)
OR (95% CI) P value Pc value
IL-1α (−889) (C/T)
C 323 (51.8%) 351 (57.4%) Reference –
T 301 (48.2%) 261 (42.6%) 0.798 (0.638–0.999) 0.048 1
CC 85 (27.2%) 107 (35%) Reference –
CT 153 (49.1%) 137 (44.8%) 0.711 (0.493–1.026) 0.068
TT 74 (23.7%) 62 (20.2%) 0.666 (0.428–1.035) 0.071
IL-1β (−511) (C/T)
C 323 (51.8%) 310 (50.7%) Reference –
T 301 (48.2%) 302 (49.3%) 1.045 (0.836–1.307) 0.696
CC 82 (26.3%) 74 (24.2%) Reference –
CT 159 (51%) 162 (52.9%) 1.129 (0.770–1.656) 0.535
TT 71 (22.7%) 70 (22.9%) 1.093 (0.693–1.723) 0.704
IL-1β (−31) (C/T)
C 347 (55.6%) 334 (54.6%) Reference –
T 277 (44.4%) 278 (45.4%) 1.043 (0.833–1.305) 0.715
CC 102 (32.7%) 96 (31.4%) Reference –
CT 143 (45.8%) 142 (46.4%) 1.055(0.734–1.516) 0.772
TT 67 (21.5%) 68 (22.2%) 1.078 (0.696–1.670) 0.735
IL-1β (+3953) (C/T)
C 347 (56%) 286 (47%) Reference –
T 277 (44%) 326 (53%) 1.428 (1.141–1.786) 0.002 0.012
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troversial. This may be partly due to small sample sizes and different
populations (Huang et al., 2013). The purpose of the present study
was to address the association between polymorphisms and haplotypes
of the IL1 gene cluster and MS susceptibility in an Iranian population.
2. Materials and methods
2.1. Subjects
In this population-based association study, 618 Iranian subjects in-
cluding 306unrelatedMS patients and 312 healthy controlswere inves-
tigated for genetic variations in the IL-1 gene cluster. The study was
approved by the Ethics Committee of Golestan University of Medical
Sciences (No: 26279010188) andwritten informed consentwas obtain-
ed fromall patients andhealthy control subjects.MS patientswere diag-
nosed by expert neurologists based on clinical and paraclinical ﬁndings
(MRI, oligoclonal bands in CSF, and evoked potentials) according to
McDonald's criteria (Mcdonald et al., 2001). The control group consisted
of 312 healthy subjects of the same ethnic origin as MS patients also
matched for age and sex. They were recruited from the Blood Transfu-
sion Organization of Gorgan city, northeast of Iran. None of them had
a history of autoimmune or inﬂammatory diseases. A demographic
questionnaire that included sex, age, age at onset, expanded disability
status scale (EDSS) and the type of MS was prepared for MS patients.
The demographic data for MS patients is summarized in Table 1.
2.2. Nucleic acid extraction and genotyping
DNA was extracted from peripheral blood cells as previously de-
scribed (Shahbazi et al., 2002). Polymorphisms of the IL-1 gene cluster
including IL-1α −889, IL-1β −511, IL-1β −31, and IL-1β +3953
were genotyped by sequence-speciﬁc primer-polymerase chain reac-
tion (SSP-PCR) method as described previously (Bioque et al., 1995,
Hayashi et al., 2009, Hutyrova et al., 2002, Tarlow et al., 1993). An inter-
nal positive control primer pair, which ampliﬁes a conserved region of
the Human Growth Hormone gene, is included in every PCR reaction
mix. After PCR and agarose gel electrophoresis, the genotyping results
were evaluated by the presence or absence of an allele-speciﬁc PCR
product (graphical abstract). A subset of samples was subject to DNA
sequencing to conﬁrm the genotyping results (data not shown). Each
allele of IL-1RA VNTR was identiﬁed according to its size, as previously
described by others (Hutyrova et al., 2002).
2.3. Statistical analysis
Genotype frequencies were tested for Hardy–Weinberg equilibrium
by χ2 analysis. The possible differences in genotype and allele frequen-
cies were assessed by the Pearson's Chi-square test, and the risk associ-
ated with genotypes/alleles was calculated as the odds ratio (OR) with
95% conﬁdence intervals (CIs). A multiple logistic and linear regression
analysis was performed to evaluate possible associations between the
variables. All statistical analysis was performed using the SPSS software,Table 1
demographic data of MS patients (n = 306).
Mean age 32.2 ± 8.6 years
Female/male 183/123
EDSS 3.4 ± 1.9
Age at onset 26 ± 7
Duration (years)
Clinical subtype
Relapsing-remitting (RR) 254 (83%)
Primary-progressive (PP) 44 (14.4%)
Secondary-progressive (SP) 4 (1.3%)
Progressive-relapsing (PR) 4(1.3%)
Abbreviations: EDSS expanded disability status scale.version 16. Differences were considered signiﬁcant when the P value
was b0.05. Bonferroni correction for multiple testing was used for
signiﬁcant P values of the genotypes. Corrected (Pc) values b0.05 were
considered signiﬁcant.2.4. Linkage disequilibrium (LD) and haplotype analysis
The estimation of haplotype frequency and the analysis of associa-
tions between different haplotypes and MS risk were implemented
with SNPStats online software [http://bioinfo.iconcologia.net/snpstats/
start.htm] using the expectation–maximization (EM) algorithm (Sole
et al., 2006). Also, LD analysis was performed using this program
based on the genotype data of the IL-1β−31 (rs1143627), and IL-1β
−511 (rs16944) polymorphisms.3. Results
To examine the association of IL-1 cluster gene polymorphismswith
MS, ﬁve polymorphic regions (four SNPs and one VNTR) were investi-
gated as follows. The distribution of genotypes and alleles of the IL-1α
−889, IL-1β −511, IL-1β −31, IL-1β +3953 and IL-1Ra VNTR in
healthy controls and MS patients is shown in Table 2.CC 104 (33.3%) 73 (23.9%) Reference –
CT 139 (44.5%) 140 (45.8%) 1.43 (0.98–2.10) 0.0001 0.002
TT 69 (22.1%) 93 (30.4%) 1.92 (1.25–2.96) 0.005 0.01
IL-1Ra VNTR
A1 414(66.3%) 395 (64.5%) Reference –
A2 198(31.7%) 200 (32.7%) 0.673(0.318–1.428) 0.303
A3 12(2%) 17 (2.8%) 0.713(0.332–1.532) 0.386
A1A1 162(52%) 148 (48.4%) Reference –
A2A2 60(19.2%) 59 (19.3%) 1.076(0.705–1.643) 0.733
A1A2 78(25%) 82 (26.8%) 1.151(0.786–1.686) 0.471
A1A3 12(3.8%) 17 (5.5%) 1.551(0.717–3.355) 0.265
Abbreviations:MS Multiple sclerosis, IL Interleukin, A allele, VNTR variable number of
tandem repeats, OR odds ratio, CI conﬁdence interval, Pc value = corrected P value after
including Bonferroni's multiple testing correction [P value multiplied by the number of
comparisons].
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There was no association between IL-1α-889 genotypes with MS
(Table 2). Comparison of the IL-1α-889 genotypes revealed that the
C/C genotype was overrepresented in MS patients compared with
healthy controls (35% versus 27.2%), whereas the frequency of C/T and
T/T genotypes in healthy controls were more than MS patients (44.8%
versus 49.1% and 20.2% versus 23.7%, respectively). However, compari-
son of IL-1α−889 T risk allele frequencies in the subject and control
groups revealed a negative, borderline- signiﬁcant association with
MS [OR = 0.798, 95% CI (0.638–0.999), P value = 0.048]. However, it
failed to remain signiﬁcant after applying Bonferroni correction.
3.2. IL-1 β polymorphisms
Three polymorphic regions of IL-1 β gene, including IL-1β −511,
−31 and +3953 were investigated. The distribution of the IL-1β
−511 genotypes and alleles did not signiﬁcantly differ between the
MS patients and healthy controls (Table 2). No signiﬁcant differences
were observed between MS patients and healthy controls in the geno-
type and allele frequencies of the IL-1β−31 polymorphism (Table 2).
For IL-1β+3953 gene polymorphism, distribution of the C/T geno-
type was signiﬁcantly different between the MS patients and healthy
controls when compared to the C/C reference genotype [OR = 1.43,
95% CI (0.98–2.10), P= 0.0001, Pc = 0.0002] (Table 2). The T/T geno-
type frequency of IL-1β+3953 in the MS patients and healthy controls
was also signiﬁcantly different when compared to the C/C reference ge-
notype [OR=1.92, 95% CI (1.25–2.96), P=0.005, Pc=0.001] (Table 2).
The T allele frequency, compared to the C reference allele, was signiﬁ-
cantly higher in MS patients than the controls [OR = 1.428, 95% CI
(1.141–1.786), P value = 0.002, Pc = 0.012] (Table 2).
3.3. IL-1Ra polymorphism
No signiﬁcant differences were observed between MS patients and
healthy controls in the genotype and allele frequencies of the IL-1Ra
polymorphism. A2/A3 and A3/A3 genotypes were not observed in our
study (Table 2).
3.4. Association of IL-1 gene polymorphisms with MS under different
inheritance models
The association of the four SNPs in the IL-1 gene with MS was
estimated by calculating pooled odds ratio (OR) and 95% conﬁdence in-
tervals (CI) under co-dominant, dominant and recessive genetic
models. Based on the assumption that T, the more frequent allele, is a
risk allele, these genetic models compares C/C genotypes to C/T + T/T
genotypes in dominant model and C/C + C/T to T/T genotypes in
recessive model. In the co-dominant model, the genotype frequencies
were compared between the MS patients and healthy controls and aTable 3
polymorphisms in the IL-1 cluster gene polymorphisms and MS risk under Co-dominant mode
Position genotype Healthy controls (n = 312)
IL-1α (−889) (C/T) C/C 85 (27.2%) 1
C/T 153 (49%) 1
T/T 74 (23.7%)
IL-1β (−511) (C/T) C/C 82 (26.3%)
C/T 159 (51%) 1
T/T 71 (22.8%)
IL-1β (−31) (C/T) C/C 102 (32.7%)
C/T 143 (45.8%) 1
T/T 67 (21.5%)
IL-1β (+3953) (C/T) C/C 104 (33.3%)
C/T 29 (9.3%)
T/T 69 (22.1%)
Pcvalue = corrected P value after including Bonferroni's multiple testing correction (P value msigniﬁcant association with MS was observed in IL-1β, +3953 (OR =
1.43, 95% CI (0.98–2.10) p= 0.011, Pc = 0.022) (Table 3). Also, signiﬁ-
cant association was observed in IL-1β, +3953 (OR = 1.60, 95% CI
(1.12–2.27) P = 0.009, Pc = 0.0018) when the effect of the polymor-
phismwas considered under a dominant geneticmodel (Table 4). In ad-
dition, a signiﬁcant association was found in IL-1β, +3953 (OR= 1.54,
95% CI (1.07–2.21) p = 0.019, Pc = 0.038) under a recessive genetic
model (C/C + C/T vs. T/T) (Table 5).
3.5. Association of IL-1 gene haplotypes with MS
Since only rs1143627 (IL-1β−31), and rs16944 (IL-1β−511) posi-
tions showed moderate LD (D′ = 0.1546, r = 0.143 and P value =
0.00001), haplotype analysis was only performed for these SNPs
(Table 6). Therefore, the SNP order which deﬁned the haplotype
structure was rs1143627 (IL-1β −31), and rs16944 (IL-1β −511),
respectively. Haplotype analysis with the EM algorithm revealed a
signiﬁcantly higher presence of two haplotypes H3 (CT) and H4 (TC)
in healthy controls than the MS patients (Global haplotype association
p-value = 0.025) (Table 6), thereby suggesting protective roles for
them against MS. However, neither of them remained signiﬁcant after
applying Bonferroni's multiple testing corrections.
4. Discussion
The imbalance between pro- and anti-inﬂammatory cytokines is one
of the landmarks in MS development and progression (Link, 1998,
Mihailova et al., 2005). Thus, speciﬁc gene polymorphisms in IL-1
gene, as a pro-inﬂammatory cytokine, may contribute to the pathogen-
esis of MS (Dinarello, 1996, Huang et al., 2013, Reboul et al., 2000,
Schrijver et al., 2003, Trevilatto et al., 2011) through dysregulation of
IL-1 expression. Several studies have been carried out to test the
hypothesis that genetic polymorphisms in the IL-1 gene family might
be associated with MS risk; however data have yielded conﬂicting
results. In this regard, more replication studies on different populations
may be help establish a valid genotype–phenotype association
(Chanock et al., 2007). In the present study, we assessed the association
of IL-1 gene cluster polymorphisms with susceptibility to MS in 618
Iranian subjects including 306 MS patients and 312 healthy-matched
controls. The functional signiﬁcance of the promoter region in the regu-
lation of IL-1α gene expression has been shown in several studies
(Dominici et al., 2002, Hulkkonen et al., 2000, Mora et al., 1990). Domi-
nique R, et al. showed that the IL-1α (−889) C/C genotype was associ-
ated with a signiﬁcantly lower gene transcription and lower level of IL-
1α in plasma compared with the T/T genotype (Dominici et al., 2002).
Also, Shirodaria S, et al. showed that the presence of the T allele in the
IL-1α−889 C/T promoter is associated with a fourfold increase in IL-
1α expression (Shirodaria et al., 2000). Contradictory ﬁndings have re-
ported no evidence for the association between the IL-1α −889 C/T
polymorphism and MS risk (Huang et al., 2013). No association wasl.
MS patients (n = 306) OR (95%CI) P value Pcvalue
07 (35%) 1.00 –
37 (44.8%) 0.71 (0.49–1.03) 0.11
62 (20.3%) 0.67 (0.43–1.04)
74 (24.2%) 1.00 –
62 (52.9%) 1.13 (0.77–1.66) 0.82
70 (22.9%) 1.09 (0.69–1.72)
96 (31.4%) 1.00 –
42 (46.4%) 1.06 (0.73–1.52) 0.94
68 (22.2%) 1.08 (0.70–1.67)
73 (23.9%) 1.00 –
55 (18%) 1.43 (0.98–2.10) 0.011 0.022
93 (30.4%) 1.92 (1.25–2.96)
ultiplied by the number of comparisons).
Table 4
polymorphisms in the IL-1 cluster gene polymorphisms and MS risk under Dominant model.
Position genotype Healthy controls (n = 312) MS patients (n = 306) OR (95%CI) P value Pc value
IL-1α (−889) C/C 85 (27.2%) 107 (35%) 1.00 –
C/T–T/T 227 (72.8%) 199 (65%) 0.70 (0.49–0.98) 0.038 0.078
IL-1β (−511) C/C 82 (26.3%) 74 (24.2%) 1.00 –
C/T–T/T 230 (73.7%) 232 (75.8%) 1.12 (0.78–1.61) 0.55
IL-1β (−31) C/C 102 (32.7%) 96 (31.4%) 1.00 –
C/T–T/T 210 (67.3%) 210 (68.6%) 1.06 (0.76–1.49) 0.73
IL-1β (+3953) C/C1 04 (33.3%) 73 (23.9%) 1.00 v
C/T–T/T 208 (66.7%) 233 (76.1%) 1.60 (1.12–2.27) 0.009 0.018
Pcvalue = Corrected P value after including Bonferroni's multiple testing correction (P value multiplied by the number of comparisons).
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line with previous studies (Huang et al., 2013).
However, a mild statistically signiﬁcant difference was observed
between the frequency of the T allele in healthy controls and MS
patients (48.2% versus 42.6%, P= 0.048) (Table 2)which did not remain
signiﬁcant after correction by Bonferroni's method. This ﬁnding
supports previous reports (Huang et al., 2013). Also, a signiﬁcant associ-
ation found between MS and the IL-1α−889 C/T polymorphism under
a dominant genetic model failed to persist after Bonferroni's correction
(OR= 0.70 (95% CI) 0.49–0.98, P= 0.038, Pc= 076) (Table 4). The re-
sult of Sarial S et al. showed that the IL-1α (−889) T/C and T/T geno-
types were associated with MS disease in an Iranian population (Sarial
et al., 2008). Here, differences were also observed between MS and
control groups in TC and TT genotype frequencies, but they were not
statistically signiﬁcant. Elevated levels of IL-1 β cytokine within the
MS lesions and sera of MS patients have been described previously
(Cannella and Raine, 1995, Dujmovic et al., 2009, Heesen et al., 2000).
To date, several studies with debatable conclusions have been to per-
form to explain the role of genetic polymorphisms in IL-1β expression.
Association of IL-1β C-511T polymorphisms with the susceptibility to
several diseases has been reported (Nemetz et al., 2001, Wang et al.,
2003, Wang et al., 2002), however, no association has been found
between IL-1β C-511T polymorphisms and MS risk in previous stud-
ies (Aggelakis et al., 2010, Ferri et al., 2000, Hooper-Van Veen et al.,
2003, Luomala et al., 2001, Mann et al., 2002, Mirowska-Guzel et al.,
2011, Niino et al., 2001), except for a few cases in recent years. The
results of Borzani I et al. showed the association between the IL-1β
C-511T variant and MS in an Italian Caucasian population (Borzani
et al., 2010). Also, the results of Isik N, et al. suggested a protective
role for the 2/2 genotype of IL-1β −511 in the Turkish population
(Isik et al., 2013). However, meta-analyses failed to ﬁnd an associa-
tion between the IL-1β C-511T and MS risk (Huang et al., 2013,
Nikolopoulos et al., 2011).
In the present study, we found no signiﬁcant difference in the allele
frequency of the IL-1β C-511T variant between healthy controls andMS
patients (OR= 1.045, 95% CI (0.836–1.307) P=0.696) (Table 2). (Ferri
et al., 2000, Luomala et al., 2001, Niino et al., 2001, Mann et al., 2002,
Hooper-Van Veen et al., 2003, Aggelakis et al., 2010, Mirowska-Guzel
et al., 2011). Also, no association was observed between MS and
the IL-1β C-511T polymorphism when it was considered under co-Table 5
polymorphisms in the IL-1 cluster gene polymorphisms and MS risk under Recessive model.
Position genotype Healthy controls (n = 312) MS
IL-1α (−889) C/C–C/T 238 (76.3%) 244
T/T 74 (23.7%) 62
IL-1β (−511) C/C–C/T 241 (77.2%) 236
T/T 71 (22.8%) 70
IL-1β (−31) C/C–C/T 245 (78.5%) 238
T/T 67 (21.5%) 68
IL-1β (+3953) C/C–C/T 243 (77.9%) 213
T/T 69 (22.1%) 93
Pc value = Corrected P value after including Bonferroni's multiple testing correction (P value mdominant, dominant and recessive genetic models (Table 2). This ﬁnd-
ing is consistent with those of some previous investigations (Huang
et al., 2013). The results of Kimura et al. showed that expression of the
IL-1β−31T allele is signiﬁcantly higher than that of the IL-1β−31C al-
lele in EBV-transformed lymphoblastoid cell lines (Kimura et al., 2004).
This ﬁnding may correspond to the fact that -31T allele is located in a
TATA box facilitating the formation of the transcription initiation com-
plex (El-Omar et al., 2000), and the change from IL-1β−31T to IL-1β
−31C (e.g. the change of motif from TATAAA to CATAAA) leads to de-
crease efﬁciency of the promoter, thereby decreasing the IL-1β expres-
sion (Hayashi et al., 2009, Lind et al., 2007, Wobbe and Struhl, 1990). In
this study, the allele frequency of IL-1β −31T was not signiﬁcantly
higher in the MS patients (OR = 1.043, 95% CI (0.833–1.305) P =
0.715) (Table 2). Also, no association was observed between the MS
risk and the IL-1β −31C N T polymorphism when it was considered
under co-dominant, dominant and recessive genetic models (Table 2).
In our population, in agreement with recent ﬁndings in the Italian pop-
ulation (Borzani et al., 2010), we did not ﬁnd any association between
the IL-1β -31C N T polymorphism and MS.
A polymorphism in the IL-1β+3953, especially the IL-1β+3953 T
allele has been associated with the increased IL-1β synthesis in several
immune-inﬂammatory diseases (Chen et al., 2006, Ferreira et al.,
2008, Gore et al., 1998, Hulkkonen et al., 2000, Pociot et al., 1992). How-
ever, previous reports failed to ﬁnd evidence supporting the contribu-
tion of the IL-1β+3954 gene in susceptibility to MS (Aggelakis et al.,
2010, Borzani et al., 2010, Dincic et al., 2006, Hooper-Van Veen et al.,
2003, Kantarci et al., 2000, Luomala et al., 2001, Mann et al., 2002,
Niino et al., 2001, Schrijver et al., 1999,Wansen et al., 1997). Our results
support the possible role of IL-1β+3953 polymorphism in susceptibil-
ity toMS in the studied Iranian population. A signiﬁcant associationwas
found for the IL-1β+3953 T/T genotype andMS risk [OR=1.92, 95% CI
(1.25–2.96), P value = 0.005, Pc = 0.01]. Interestingly, the risk IL-1β
+3953T allele was signiﬁcantly higher than the common IL-1β
+3953 C allele in MS patients [OR = 1.428, 95% CI (1.141–1.786),
P value = 0.002, Pc = 0.01]. This inconsistency may be due to
ethnicity-related differences in the frequencies of polymorphic
alleles. In addition, there was a signiﬁcant association between IL-
1β+3953T/C polymorphism and MS risk in our population when the
effect of the polymorphism was considered under co-dominant and
recessive genetic models (for more detail, see Table 2).patients (n = 306) OR (95% CI) P value Pc value
(79.7%) 1.00
(20.3%) 0.82 (0.56–1.20) 0.3
(77.1%) 1.00 –
(22.9%) 1.01 (0.69–1.47) 0.97
(77.8%) 1.00 –
(22.2%) 1.04 (0.71–1.53) 0.82
(69.6%) 1.00 –
(30.4%) 1.54 (1.07–2.21) 0.019 0.019
ultiplied by the number of comparisons).
Table 6
Analysis of haplotype frequencies and their association with MS disease, adjusted by sex and age.
Haplotype IL-1β−31 IL-1β−511 Healthy controls MS patients OR (95% CI) P value Pcvalue
H1 C C 29.08% 35.02% 1 –
H2 T T 21.7% 29.8% 1.07 (0.78–1.45) 0.69
H3 C T 26.53% 19.55% 0.66 (0.45–0.96) 0.029a 0.087
H4 T C 22.69% 15.63% 0.65 (0.45–0.94) 0.023b 0.069
Global haplotype association P-value 0.025c
Data are expressed as (%). Haplotype frequencies and P values were estimated using the implementation of the EM algorithm executed by SNPStats. The most frequent haplotype among
patients served as the referent.
Pc value = Corrected P value after including Bonferroni's multiple testing correction (P value multiplied by the number of comparisons).
a These haplotypes were negatively associated with susceptibility to MS.
b These haplotypes were negatively associated with susceptibility to MS.
c Signiﬁcant global haplotype association P value.
118 A. Khosravi et al. / Journal of Neuroimmunology 288 (2015) 114–119The interleukin-1 receptor antagonist (IL-1ra) is a naturally occur-
ring antagonist that competes with IL-1β for the IL-1 receptor, thereby
preventing activation of the target cells (Arend, 1991). Previous studies
performed in the animal model for MS and experimental autoimmune
encephalomyelitis (EAE) indicated that IL-1Ra might affect disease
susceptibility and progression (Badovinac et al., 1998). However, the
inﬂuence of IL-1ra VNTR polymorphism on MS risk is controversial
(Crusius et al., 1995, Kantarci et al., 2000, Mann et al., 2002, Niino
et al., 2001, Schrijver et al., 1999, Sciacca et al., 1999, Wansen et al.,
1997). Previous studies have reported the association of different
IL-1ra alleles with MS, including the A2 allele (Crusius et al., 1995),
the A1 allele (Sciacca et al., 1999) and the rare IL-1ra allele 3 (Kantarci
et al., 2000). However, we could not ﬁnd any association between
these polymorphisms andMS risk. Thus, our results are in linewith pre-
vious studies (Huang et al., 2013). Althoughﬁve alleles have, so far, been
described in IL-1ra VNTR polymorphism, two alleles (A1 and A2) ac-
count for approximately 99% of all identiﬁed IL-1ra polymorphisms
(Tarlow et al., 1993). In this study, approximately 97.6% of identiﬁed
IL-1ra alleles were A1 and A2, and A3 comprised 2.4% (see Table 2).
In this study, a signiﬁcant association was found between IL-1β
+3953 T/C polymorphism and MS risk in our population under co-
dominant, dominant and recessive genetic models (for more detail,
see Tables 3-5). However, no association was observed between MS
and either of the IL-1β−511C N T or IL-1β−31C N T polymorphisms
under all genetic models (Table 2). Statistically signiﬁcant LDwas iden-
tiﬁed among IL1β −31 (rs1143627) and the IL1β −511 (rs16944)
alleles (D’ = 0.1546, r = 0.143 and P value = 0.00001). Our ﬁnding
was in agreementwith the study of Borzani et al. in an Italianpopulation
(Borzani et al., 2010). Furthermore, Haplotype analysis initially identi-
ﬁed two haplotypes in IL-1 gene (H3 andH4) thatwere negatively asso-
ciatedwith susceptibility toMS (p value=0.029 and 0.023, respectively
(Table 6). Upon applying bonferroni's multiple testing correction, nei-
ther of these haplotypes remained signiﬁcant. Since the latter correction
is very conservative and may sometimes lead to false negative results
the data should be interpreted cautiously.5. Conclusion
Our data suggest that the IL-1β+3953 T/C gene polymorphismmay
be associated with susceptibility to MS in the Iranian population, in
contrast to previous studies. Given that there are no previous reports
about the association of the IL-1β+3953 T/C polymorphism and MS,
this association may be due to ethnic differences. Although our results
together with the others contribute to understanding the genetic sus-
ceptibility of MS risk, further comprehensive clinical and molecular
studies are needed to elucidate the role of IL-1 family in MS.Conﬂict of interest statement
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